Immunogenicity and protective efficacy of "mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route

Infection and Immunity

Volumn 77, Issue 1, 2009, Pages 223-231

  Gupta, Ankan ^a   Geetha, Nishamol ^a,c   Mani, Jiju ^a   Upadhyay, Pramod ^a   Katoch, V M ^b   Natrajan, M ^b   Gupta, U D ^b   Bhaskar, Sangeeta ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INACTIVATED VACCINE; INTERLEUKIN 12; LIVE VACCINE; MYCOBACTERIUM W VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; LEPROSY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM W; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BCG VACCINE; BRONCHOALVEOLAR LAVAGE FLUID; CELL PROLIFERATION; CYTOKINES; IMMUNOGLOBULIN A; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTES; MACROPHAGES; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 58449114469     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00526-08     Document Type: Article

References (30)

1. Barber, D. L., E. J. Wherry, D. Masopust, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
2. Bevan, M. J. 2002. Immunology: remembrance of things past. Nature 420:748-749.
3. Bhaskar, S., and P. Upadhyay. 2003. Design and evaluation of an aerosol infection chamber for small animals. Int. J. Pharm. 255:43-48.
4. Brandtzaeg, P., I. N. Farstad, and G. Haraldsen. 1999. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today 20:267-277.
5. + T cells activated in cutaneous or mucosal lymphoid tissues. J. Exp. Med. 195:135-141.
6. Chan, J., Y. Xing, R. S. Majliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111-1122.
7. Chen, L., J. Wang, A. Zganiacz, and Z. Xing. 2004. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72:238-246.
8. Collins, D. M. 2000. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Immunol. Cell Biol. 78:342-348.
9. Derby, E., V. Reddy, M. Baseler, and A. Malyguine. 2001. Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effector cell phenotype. BioTechniques 31:660-665.
10. Falero-Diaz, G., S. Challacombe, D. Banerjee, G. Douce, and J. Ivanyi. 2000. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18:3223-3229.
11. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129.
12. Kamath, A. T., U. Fruth, M. J. Brennan, K. B. Walker, and M. Liu. 2005. New live mycobacterial vaccines: the Geneva consenses on essential steps towards clinical development. Vaccine 23:3753-3761.
13. Katoch, K., and V. M. Katoch. 1995. Treatment of bacilliferrous BL/LL cases with combined chemotherapy and immunotherapy. Int. J. Lepr. 63:202-212.
14. Kaufmann, S. H. 2001. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1:20-30.
15. Leemans, J. C., T. Thepen, S. Weijer, S. Florquin, and T. V. D. Poll. 2005. Macrophages play a dual role during pulmonary tuberculosis in mice. J. Infect. Dis. 191:65-74.
16. McGhee, J. R., C. Czerkinsky, and J. Mestecky. 1999. Mucosal vaccines: an overview, p. 741-757. In P. L. Ogra, M. E. Lamm, J. Bienenstock, J. Mestecky, and J. R. McGhee (ed.), Mucosal immunology, 2nd ed. Academic, London, United Kingdom.
17. Patel, N., M. M. Deshpande, and M. Shah. 2002. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J. Indian Med. Assoc. 100:191-193.
18. Reddi, P. P., A. G. Amin, P. S. Khandekar, and G. P. Talwar. 1994. Molecular definition of unique species status of Mycobacterium w; a candidate leprosy vaccine strain. Int. J. Lepr. Other Mycobact. Dis. 62:229-236.
19. Rodríguez, A., A. Tjarnlund, J. Ivanji, M. Singh, M. T. Blomberg, and C. Fernandez. 2005. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 23:2565-2572.
20. + CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages. J. Immunol. 165:353-363.
21. Sharma, P., R. Mukherjee, G. P. Talwar, K. G. Sarathchandra, and P. Singh. 2005. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr. Rev. 76:127-143.
22. Singh, I. G., R. Mukherjee, and G. P. Talwar. 1991. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w. Vaccine 9:10-13.
23. Singh, I. G., R. Mukherjee, G. P. Talwar, and S. H. E. Kaufmann. 1992. In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infect. Immun. 60:257-263.
24. Talwar, G. P., N. Ahmed, and V. Saini. 2007. The use of the name Mycobacterium w for the leprosy immunotherapeutic bacillus creates confusion with M. tuberculosis-W (Beijing strain): a suggestion. Infect. Genet. Evol. 8:100-101.
25. Talwar, G. P., S. A. Zaheer, R. Mukherjee, R. Walia, and N. R. Suresh. 1990. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 8:121-129.
26. van Rie, A., R. Warren, M. Richardson, T. C. Victor, R. P. Gie, D. A. Enarson, N. Beyers, and P. D. van Helden. 1999. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341:1174-1179.
27. Williams, A., R. Reljic., I. Naylor., P. D. Marsh., and J. Ivanyi. 2004. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 111:328-333.
28. Worku, S., and D. F. Hoft. 2003. Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth. Infect. Immun. 71:1763-1773.
29. Yadava, A., and R. Mukherjee. 1993. An immunodominant 30-kDa antigen of a candidate anti-leprosy vaccine, Mycobacterium w, shares T and B cell determinants with M. leprae and M. tuberculosis. Med. Microbiol. Immunol. 182:243-253.
30. Zaheer, S. A., R. Mukherjee, B. Ramkumar, R. S. Misra, A. K. Sharma, H. K. Kar, H. Kaur, S. Nair, A. Mukherjee, and G. P. Talwar. 1993. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167:401-410.